MindMed Announces New Employee Inducement Grants
Mind Medicine (MindMed) (NASDAQ:MNMD) was upgraded by analysts at Chardan Capital to a "strong-buy" rating.
Mind Medicine (MindMed) (NASDAQ:MNMD) had its price target raised by analysts at Canaccord Genuity Group Inc. from $16.00 to $25.00. They now have a "buy" rating on the stock.
Mind Medicine (MindMed) (NASDAQ:MNMD) had its price target lowered by analysts at Royal Bank Of Canada from $21.00 to $20.00. They now have an "outperform" rating on the stock.
Mind Medicine Inc (MNMD) Q3 2025 Earnings Call Highlights: Strategic Advances and Financial ... [Yahoo! Finance]